The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2011Validation of Lysosomal Enzymes Assay in CSF - One-year Extension of the RRIA: CSF Lysosomal Hydrolases' Activity as Possible Marker of Parkinson's Disease
Promising Outcomes of Original Grant:
To date, there is no accepted diagnostic test based on biochemical analysis of blood or cerebrospinal fluid (CSF) for clinical diagnosis of PD. Recent studies... -
Therapeutics Development Initiative, 2011Proof of Concept of Treatment with Novel Hydroxypyridinone Iron Chelators in a Non-Clinical Model of Parkinson's Disease
Objective/Rationale:
We will test two novel, orally bioavailable, brain-penetrant iron chelators in a pre-clinical model of Parkinson’s disease (PD) for their ability to reduce labile iron-associated... -
MJFF Research Grant, 2011Analysis of a Viral Non-coding RNA as a Novel Therapeutic in a Chronic MPTP Pre-clinical Model of Parkinson's Disease and its Mechanism of Mitochondrial Protection
Promising Outcomes of Original Grant:
Previously, we identified a viral RNA which could act as a novel protective agent in models of PD, when delivered before experimental damage to neurons of the... -
Dyskinesia, 2011The Nur77/RXR Transcriptional Complex as a New Target in L-Dopa-induced Dyskinesia Treatment
Objective/Rationale:
Transcription factors are nuclear proteins that regulate gene expression. They are likely to play an important role in long-term molecular maladaptive processes such as those... -
Rapid Response Innovation Awards, 2011Informing Clinical Decision Making in the Pre-motor Period of Parkinson Disease
Objective/Rationale:
Currently, the diagnosis of Parkinson disease (PD) relies on recognition of impaired movement, which occurs decades after neurodegeneration begins. By looking at changes in sleep... -
Rapid Response Innovation Awards, 2011Development of Dopaminergic Cell Line Models of Alpha-synuclein Expression for High-throughput Drug Screenings and Monitoring of Alpha-synuclein Expression
Objective/Rationale:
Parkinson’s disease (PD) affects millions of people in the United States, and it is caused by the death of neurons that produce dopamine. A large body of experimental evidence...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.